MedPath

A study to compare efficacy of Abhyanga with Mahanarayana taila as an add on to the standard of care versus standard of care alone in chemotherapy induced peripheral neuropathy

Phase 3
Conditions
Health Condition 1: G620- Drug-induced polyneuropathy
Registration Number
CTRI/2023/11/059688
Lead Sponsor
Dr Namboodiri Aiswarya Raman
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1)Neuropathy attributed to chemotherapeutic agents with no prior history of attributable cause for chemotherapy induced peripheral neuropathy.

2)Eastern Cooperative Oncology Group (ECOG) Performance Status less than or equal to 3.

3)Self-reported neuropathy score greater than or equal to 3 on 0-10 scale and/or grade 2 or 3 neuropathy according to NCI-CTCAEv5 criteria.

4)Life expectancy more than 3 months.

5)Those who are willing to participate in this study and sign informed consent forms.

Exclusion Criteria

1)Peripheral neuropathy other than those induced by neurotoxic chemotherapeutic agents.

2)Abnormal cognition and speech - causing difficulty in comprehension, expression and signing informed consent

3)Age below 18 and above 60 years.

4)Pregnancy, lactating mothers.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath